Compare RDCM & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDCM | INDP |
|---|---|---|
| Founded | 1985 | 2000 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.2M | 171.9M |
| IPO Year | 1999 | 2021 |
| Metric | RDCM | INDP |
|---|---|---|
| Price | $10.23 | $1.06 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $18.00 | N/A |
| AVG Volume (30 Days) | ★ 173.8K | 103.7K |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.50 | N/A |
| Revenue Next Year | $9.74 | N/A |
| P/E Ratio | $16.35 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.40 | $0.92 |
| 52 Week High | $16.74 | $8.57 |
| Indicator | RDCM | INDP |
|---|---|---|
| Relative Strength Index (RSI) | 29.89 | 28.58 |
| Support Level | $9.40 | $0.92 |
| Resistance Level | $13.27 | $3.00 |
| Average True Range (ATR) | 0.43 | 0.21 |
| MACD | -0.07 | -0.04 |
| Stochastic Oscillator | 20.83 | 2.58 |
Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.